This site is intended for Healthcare professionals only.
Elsevier-Clinicalkey

Lundbeck gets DCGI nod for Brintellix antidepressant, launches in India


Lundbeck gets DCGI nod for Brintellix antidepressant, launches in India

Brintellix, is a novel multimodal antidepressant, which has been specifically designed to inhibit serotonin reuptake and modulate serotonergic receptor activity of the neurons in the brain of affected patients.

New Delhi: Drug firm Lundbeck Thursday said it has launched in India Brintellix tablets, which are used for treatment of Major Depressive Disorder. The company has launched the drug after getting approval from the Drug Controller General of India (DCGI), Lundbeck India said.

“We are pleased to be able to offer a new treatment option to the patients with depression which can address all the symptoms of depression, helping the patient to function better,” Lundbeck India Country Manager Maninder Singh Sahwney said.

Depression is a complex disease that involves mood, physical and cognitive symptoms, he added.

Brintellix, is a novel multimodal antidepressant, which has been specifically designed to inhibit serotonin reuptake and modulate serotonergic receptor activity of the neurons in the brain of affected patients. It has demonstrated significant efficacy in reducing the mood symptoms in adult patients with depression as measured by traditional scales like MADRS or HAMD. It has also demonstrated improvement of cognitive performance in adult patients with depression, as measured with neuropsychological tests, as e.g. DSST or RAVLT. Cognitive symptoms are part of the diagnostic criteria for depression, and include the ability to concentrate, make decisions and the ability to remember. Cognitive symptoms are both part of the acute depressive episode as well as often being a residual symptom of depression. This means that patients with depression may have difficulties performing their duties at work which leads loss of productivity and it impacts the person, his family and the society.

“When someone suffers from depression, the daily life of that person is severely affected, at home and in the workplace. Depression is a complex disease that involves mood, physical and cognitive symptoms. We are pleased to be able to offer a new treatment option to the patients with depression which can address all the symptoms of depression, helping the patient to function better,” says Maninder Singh Sahwney, Country Manager at Lundbeck India.

Lundbeck is a Denmark-based pharma company



Source: self
0 comment(s) on Lundbeck gets DCGI nod for Brintellix antidepressant, launches in India

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted